AZD6244 + Chemotherapy for Advanced Cancer

Recruiting in Palo Alto (17 mi)

+3 other locations

Overseen byJeffrey Infante, MD

Age: 18+

Sex: Any

Travel: May Be Covered

Time Reimbursement: Varies

Trial Phase: Phase 1

Waitlist Available

Sponsor: AstraZeneca

No Placebo Group

Breakthrough Therapy

Trial Summary

What is the purpose of this trial?This study is evaluating whether a combination of AZD6244 given orally twice a day with standard doses of selected chemotherapies will be safe and tolerable for cancer patients with advanced solid tumors. The highest tolerated dose of AZD6244 in combination with selected chemotherapies will be evaluated

Eligibility Criteria

This trial is for cancer patients with advanced solid tumors who have a good performance status, measurable disease, and no curative options left. They must be able to swallow pills and not have used MEK inhibitors before or been in another study within the last month.

Inclusion Criteria

My cancer can't be cured with surgery or radiation, and chemotherapy is the standard treatment for me.

I can carry out all my usual activities without help.

I can swallow capsules.

Exclusion Criteria

I have been treated with a MEK inhibitor before.

Participation in a clinical study during the last 30 days or have not recovered from side effects of an investigational study drug

My brain or spinal cord cancer has been treated, is stable for 1 month, and I'm not on steroids.

Participant Groups

The trial tests AZD6244 taken orally twice daily alongside standard chemotherapy drugs like Temsirolimus, Dacarbazine, Erlotinib, and Docetaxel. It aims to find the highest dose of AZD6244 that's safe when combined with these chemotherapies.

4Treatment groups

Experimental Treatment

Group I: 4Experimental Treatment2 Interventions

AZD6244 + Temsirolimus

Group II: 3Experimental Treatment2 Interventions

AZD6244 + Erlotinib

Group III: 2Experimental Treatment2 Interventions

AZD6244 + Dacarbazine

Group IV: 1Experimental Treatment2 Interventions

AZD6244 + docetaxel